CSIMarket Company Name, Ticker, Competitors, else..
 
Springworks Therapeutics Inc   (NASDAQ: SWTX)
 
Price: $46.9900 $0.01 0.021%
Day's High: $47.01 Week Perf: 0.06 %
Day's Low: $ 46.98 30 Day Perf: 1.14 %
Volume (M): 5,010,800 52 Wk High: $ 0.00
Volume (M$): $ 235,457 52 Wk Avg: $0.00
Open: $46.99 52 Wk Low: $0.00



 Market Capitalization (Millions $) 3,519
 Shares Outstanding (Millions) 75
 Employees 84
 Revenues (TTM) (Millions $) 220
 Net Income (TTM) (Millions $) -258
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 20

Business Description


Springworks Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with severe rare diseases and cancer. The company's primary goal is to address unmet medical needs and improve patients' lives by advancing its robust pipeline of therapeutic candidates. Springworks Therapeutics utilizes a strategic approach that leverages its deep expertise in clinical development and collaboration with partners to efficiently bring promising therapies to market. They aim to make a significant impact on patient outcomes by discovering and developing transformative therapies.


   Company Address: 100 Washington Blvd Stamford 6902 CT
   Company Phone Number: 883-9490   Stock Exchange / Ticker: NASDAQ SWTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -10.06%    
APTO   -51%    
EXEL        0.44% 
GILD   -2%    
IOVA        4.35% 
MRNA   -9.68%    
• View Complete Report
   



Product Service News

Breakthrough Treatment EZMEKLY (mirdametinib) Receives Conditional Approval from European Commission for NF1-PN ...

Published Sat, Jul 19 2025 11:12 AM UTC

European Commission Grants Conditional Approval of EZMEKLY (mirdametinib) for Treatment of Neurofibromatosis Type 1-Associated Peripheral Nerve Sheath Tumors (NF1-PN)In a groundbreaking development for patients suffering from Neurofibromatosis Type 1 (NF1), the European Commission has granted conditional marketing authorization for EZMEKLY (mirdametinib). This marks a signi...
Clinical Study

Mirdametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas Pivotal Phase 2b ReNeu Trial Outcomes a...

Published Mon, Nov 11 2024 11:31 AM UTC

Neurofibromatosis type 1 (NF1) is a neurogenetic disorder characterized by the development of multiple tumors, most notably plexiform neurofibromas (NF1-PN). These tumors often lead to significant morbidity, impacting patient quality of life. This article presents an extensive review of the pivotal Phase 2b ReNeu trial results evaluating the efficacy and safety of mirdameti...
Clinical Study

SpringWorks Therapeutics Unveils Promising Long-Term Findings for OGSIVEO in Desmoid Tumors at 2024 CTOS Annual Meeting

Published Thu, Nov 7 2024 11:30 AM UTC

As the field of oncology continues to advance, the importance of long-term efficacy and safety data remains paramount in the development of novel therapeutics. SpringWorks Therapeutics Inc. (NASDAQ: SWTX) has made significant strides in this arena, announcing compelling findings from its Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in adults diagnosed with desmoid tumors, wh...
Clinical Study

Priority Review and Rolling Submission of Mirdametinib for NF1-PN Advancing Treatment for a Rare Genetic D...

Published Wed, Aug 28 2024 10:31 AM UTC

Recent advancements in the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) have centered around SpringWorks Therapeutics investigational MEK inhibitor, mirdametinib. This article provides an in-depth examination of the U.S. Food and Drug Administration (FDA) granting priority review to the New Drug Application (NDA) for mirdametinib, along...
Product Service News

SpringWorks Therapeutics Takes Stride Towards Augmenting NF1 Treatment with Mirdametinib NDA Submission ...

Published Mon, Jul 1 2024 10:30 AM UTC

SpringWorks Therapeutics Submits New Drug Application to FDA for Mirdametinib in Treatment of Neurofibromatosis Type 1-Plexiform NeurofibromasSTAMFORD, Conn., July 01, 2024 - SpringWorks Therapeutics, a leading biopharmaceutical company specializing in severe rare diseases and cancer, announced today the successful completion of the New Drug Application (NDA) submission to t...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 16.02
Price to Sales (Expected) -
Price to Book 8.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.5
Working Capital Ratio 4.33
Leverage Ratio (MRQ) 0.21
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.41 $
Revenues (TTM) 2.93 $
Cash Flow (TTM) -
Cash 3.84 $
Book Value 5.57 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,615,119
Net Income per Employee (TTM) -3,072,988
Receivable Turnover Ratio (TTM) 6.1
Inventory Turnover Ratio (TTM) 1.48
Asset Turnover Ratio (TTM) 0.38

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 0 %
Net Margin (MRQ) 0 %
Net Cash Flow Margin (MRQ) -12.17 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.